Exogenus Therapeutics is coordinating ExoCordOA, a five-year €13 million Horizon Europe consortium of ten organisations developing extracellular vesicle-enriched secretome therapy for osteoarthritis. The lead candidate, EXO-101, is derived from non-engineered umbilical cord blood cells and carries proteins, microRNAs and lipids intended to modulate inflammation and tissue repair, with first-in-human studies planned for early 2028. The programme explicitly targets the manufacturing, analytical and regulatory bottlenecks that have kept cell-free regenerative therapies from reaching patients.
Key Points
- €13m EU consortium advances cell-free secretome therapy for osteoarthritis
- EXO-101 uses non-engineered umbilical cord blood-derived extracellular vesicles
- Phase 1b in moderate osteoarthritis expected to begin 2028
Longevity Analysis
Secretome therapy shifts regenerative medicine away from transplanting living cells toward delivering the signaling cargo those cells release — proteins, microRNAs and lipids that instruct resident tissue to resolve inflammation and rebuild. Osteoarthritis is an apt first indication because joint degeneration reflects a sustained failure of repair signaling rather than simple mechanical wear, and the same mechanism underlies the consortium's parallel work in lung, liver and renal fibrosis. The decisive constraint is not biology but reproducibility: standardized GMP manufacturing and analytical characterization determine whether a cell-free product can be dosed consistently enough to be useful.
Original published by LT Wire.